Study Title:
A Randomized Controlled Trial Comparing Intraoperative Blood Glucose Control Between Insulin Drip Versus Insulin Boluses in Adult Cardiac Surgery Patients
Sponsor and Funding:
Sponsor: None
Funding Organization: King Faisal Specialist Hospital & Research Center, Jeddah
Study Site: Single center at King Faisal Specialist Hospital & Research Center, Jeddah
Background and Rationale:
Maintaining optimal blood glucose levels during cardiac surgery is critical for reducing postoperative complications and improving patient outcomes. Current intraoperative glucose management strategies vary, with insulin administered either continuously via infusion (drip) or intermittently as boluses. This trial investigates which method provides superior glucose control intraoperatively.
Study Design:
This is a prospective, single-center, randomized controlled trial (RCT) with two parallel arms:
Insulin drip group (continuous infusion)
Insulin bolus group (intermittent dosing)
Objectives:
Primary Objective: To compare the effectiveness of insulin drip versus insulin boluses in maintaining intraoperative blood glucose within target ranges during adult cardiac surgery.
Secondary Objectives: To assess the incidence of hypoglycemic events, insulin dose adjustments, duration of ICU stay, lactate clearance, and wound infection rates at 7- and 30-days post-surgery.
Endpoints:
Primary Endpoint: Rate of severe hypoglycemia during surgery.
Secondary Endpoints: ICU length of stay, postoperative lactate clearance, incidence of surgical wound infections at 7- and 30-days post-operation.
Participants:
Sample Size: 384 total participants, randomized equally into two groups (192 per group).
Inclusion criteria
Adults aged over 18 years undergoing cardiac surgery, preoperative blood glucose between 80-180 mg/dL, with a documented history of diabetes.
Exclusion criteria
Known intolerance to insulin, severe hepatic dysfunction, recent hypoglycemic episodes.
Intervention Protocols:
Insulin Drip Group: Continuous intravenous insulin infusion initiated at 2 units/hour, titrated to maintain target intraoperative glucose levels.
Insulin Bolus Group: Insulin administered as bolus doses every 30 minutes, adjusted based on glucose monitoring.
Data Collection and Follow-up:
Blood glucose and other relevant clinical parameters are monitored intraoperatively. Participants are followed postoperatively at 1 week, 1 month, 6 months, and 1 year to evaluate long-term outcomes and complications. The total anticipated duration of the trial is 4 years.
Statistical Analysis:
Data analysis will involve calculation of relative risk for hypoglycemia and other categorical outcomes. Time-to-event data will be analyzed using log-rank tests. Statistical significance is defined as p < 0.05.